Evidence map›Paper›PMID 34752058›Full record

ArticleACS applied materials & interfaces2021

Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen.

Niranjan Meher, Kyounghee Seo, Sinan Wang, Anil P Bidkar, Miko Fogarty, Suchi Dhrona, Xiao Huang, Ryan Tang, Charles Blaha, Michael J Evans and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Cancer nanotechnology · 2026
    Article
  9. Review
  10. Review
  11. Journal of cancer research and clinical oncology · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Niranjan MeherDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0003-3558-3712
Kyounghee SeoDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143, United States.
Sinan WangDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States.
Anil P BidkarDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0003-1249-1081
Miko FogartyDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143, United States.
Suchi DhronaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States.
Xiao HuangDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California 94158, United States.ORCID https://orcid.org/0000-0001-7733-9094
Ryan TangDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States.
Charles BlahaDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California 94158, United States.
Michael J EvansDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0003-4947-1316
David R RaleighDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143, United States.
Young-Wook JunHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143-0981, United States.ORCID https://orcid.org/0000-0003-3182-5366
Henry F VanBrocklinDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0003-2849-0841
Tejal A DesaiDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California 94158, United States.ORCID https://orcid.org/0000-0003-3409-9208
David M WilsonDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0002-1095-046X
Tomoko OzawaDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143, United States.
Robert R FlavellDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0002-8694-1199
University of California, San Francisco · US

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7M
ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response.R01AI161829 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DESAI, TEJAL A., FLAVELL, ROBERT RICHARD · 2021 to 2023
$2.4M
NCI NIH HHS P30 CA082103NIAID NIH HHS R01 AI161829
6 · The paper itself

Abstract

Boron neutron capture therapy (BNCT) is an encouraging therapeutic modality for cancer treatment. Prostate-specific membrane antigen (PSMA) is a cell membrane protein that is abundantly overexpressed in prostate cancer and can be targeted with radioligand therapies to stimulate clinical responses in patients. In principle, a spatially targeted neutron beam together with specifically targeted PSMA ligands could enable prostate cancer-targeted BNCT. Thus, we developed and tested PSMA-targeted poly(lactide-

Indexed as

AnimalsAntineoplastic AgentsBoron CompoundsBoron Neutron Capture TherapyDeferoxamineHumansMaleMiceMice, NudeMolecular StructureNanoparticlesPC-3 CellsPolyethylene GlycolsPolyglactin 910Positron-Emission TomographyProstate-Specific AntigenAntineoplastic AgentsBoron CompoundsDeferoxaminePolyethylene GlycolsPolyglactin 910poly(lactic-glycolic acid)-poly(ethyleneglycol) copolymerProstate-Specific Antigenamphiphilic block copolymerboron neutron capture therapy (BNCT)nanoparticlespositron emission tomography (PET) imagingprostate-specific membrane antigen (PSMA)

Identifiers

PMID34752058
PMCPMC12490465
OpenAlexW3214240242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.